KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Debt (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Total Debt data on record, last reported at $630.9 million in Q3 2025.

  • For Q3 2025, Total Debt rose 1318.83% year-over-year to $630.9 million; the TTM value through Sep 2025 reached $630.9 million, up 1318.83%, while the annual FY2024 figure was $51.9 million, 39.74% down from the prior year.
  • Total Debt reached $630.9 million in Q3 2025 per IONS's latest filing, roughly flat from $630.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $630.9 million in Q3 2025 and bottomed at $8.8 million in Q1 2023.
  • Average Total Debt over 5 years is $126.1 million, with a median of $57.6 million recorded in 2021.
  • Peak YoY movement for Total Debt: plummeted 82.85% in 2021, then surged 1318.83% in 2025.
  • A 5-year view of Total Debt shows it stood at $63.2 million in 2021, then crashed by 74.74% to $16.0 million in 2022, then soared by 439.46% to $86.2 million in 2023, then crashed by 39.74% to $51.9 million in 2024, then soared by 1115.07% to $630.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $630.9 million in Q3 2025, $630.1 million in Q2 2025, and $51.9 million in Q4 2024.